SAFETYCMX-020 has no respiratory depression, addiction, constipation, nausea, dizziness, fatigue, or vertigo
The use of opioids in the United States (and around the world) has created an Opioid Crisis, indeed an epidemic of opioid addiction and abuse. According to the National Institutes of Health (NIH), over 49,068 people died in the United States from the use of opioids in 2017 (NIH, 2017). The number of overdose deaths in the United States from opioids now exceeds the yearly deaths from breast cancer (41,070 in 2016) (American Cancer Society, 2017) and are near the level of HIV/AIDS yearly deaths at the peak of that epidemic (50,016 in 1995) (CDC, 2000). Most deaths associated with the use of opioids are caused by opioid’s adverse event of respiratory depression or apnea. As a pain therapy, death from respiratory depression is just one of many potential adverse events associated with opioids – in addition to nausea, vomiting, itching, constipation, and addiction, which, collectively hinder recovery in a hospital setting and potentially lead to dependency.
Opioid use often starts intravenously in a hospital setting to manage acute pain associated with accidents, injuries and surgeries. Prescribed opioid based pain therapy then commonly continues at home over longer periods of time.
Anyone who takes opioids is at risk of developing addiction leading to drug seeking behavior. Personal history and length of time that a person uses opioids play a role, but it is impossible to predict who is vulnerable to eventual dependence, abuse and death from opioids.
And the opioid crisis is not just a problem in the United States, but globally as well. For additional information concerning the global reach of the opioid epidemic, CLICK HERE.
Cmxtwenty has developed both intravenous and oral drug candidates to address the Opioid Crisis.